Objectives. To provide additional empirical findings regarding the number of pain ratings needed to obtain valid measures for assessing outcomes in pain clinical trials.
Design. Secondary analyses of data from a clinical study examining the effects of psychological treatments on pain. Eleven adults with multiple sclerosis and chronic pain reported on four domains of pain intensity (current pain and 24-hour recalled worst, least, and average pain) on four occasions before and after receiving 16 sessions of psychological pain treatments. We evaluated the reliability and validity of four single ratings and 16 different composite scores.
Results. Many of the single pain ratings were inadequately reliable while almost all of the composite scores, including the scores created from two ratings, evidenced adequate to excellent reliability. There was a noticeable increase in validity (ability to detect treatment effects) as the number of ratings used increased from one to two. However, there was little change in the validity as the number of items used to create composite scores increased from 2 to 3 or more. The findings also indicated that the scores assessing recalled worst pain were more valid than the scores assessing any of the other pain intensity domains.
Conclusions. Composite pain intensity scores created from two individual ratings of recalled pain appear to be adequately valid for detecting treatment effects. Moreover, the findings indicate that the selection of the pain intensity domain to use as a primary outcome variable may play a more important role than increasing reliability by obtaining
Introduction
Both the considerable expense of clinical trials and the acknowledged need to identify effective treatments for chronic pain has made investigators more conscious of factors that can influence our ability to detect treatment efficacy in the context of pain clinical trials [1, 2] . One of the most important of these factors is the validity of the primary outcome measure for detecting true treatment effects; without an adequately valid measure, treatments that may actually be effective could be deemed to be ineffective [3] .
The ability of a measure of pain intensity to detect real effects can be influenced by both: 1) the number of ratings used to create the pain intensity score (e.g., single vs composite scores); and 2) the specific pain intensity domain(s) assessed by the measure (i.e., current, worst, least, or average pain intensity). With respect to the number of ratings used in a composite score, a series of recent studies have suggested that only up to two ratings may be needed to have valid pain intensity reports in clinical trials of treatments for chronic painproviding they are ratings of recalled pain and not of current pain [3] [4] [5] . For example, in the first study that we are aware of that examined this question, we found that a single measure of 24-hour recalled average pain was as valid (for detecting a significant treatment effect over placebo) as composite scores made up of up to nine ratings [5] . Using a similar approach, Stone et al. [3] found that a composite score made up two ratings of recalled pain was more valid than a single rating, but not that much more valid than scores made up of more than two ratings. In a third study, we found additional evidence that only two ratings may be needed to create valid composite scores for detecting changes in pain associated with treatment [4] . If replicated in other chronic pain samples, these findings would have profound implications for the design and conduct of clinical trials, as they would indicate that outcome assessment in these studies could be greatly simplified. However, before we can make firm recommendations regarding how often to assess pain intensity in a clinical trial to obtain the most valid and useful scores, additional research is needed to confirm these preliminary findings [3, 6] .
A second important factor to consider in the selection of pain outcome measures for clinical trials is the pain intensity domain(s) to assess. A review of 34 chronic pain randomized clinical trials published in 2014 in the journals Pain, Journal of Pain, Clinical Journal of Pain, and Pain Medicine, indicate that a variety of domains of pain outcome are assessed. The most commonly used outcome measure was a single rating of recalled average pain, used in 14 of the studies. The most common recall periods used for these ratings were 24 hours (e.g., [7, 8] , and 1 week (e.g., [9, 10] ). The second most common outcome measure used was a composite score made up of individual ratings and/or the total scores from a multiple-item measure, used in 12 of the studies. However, a large variety of composite scores were used. They included, for example, an average of multiple current pain ratings from daily diaries (e.g., [11] ), an average of multiple ratings of 24-hour recalled average pain (e.g., [12] ), and an average of single ratings of different intensity domains (e.g., an average of the current pain, and 24-hour recalled least, worst, and average pain ratings from the Brief Pain Inventory [13] ). Other domains assessed in these trials included current pain (assessed in seven trials [7, [14] [15] [16] [17] [18] [19] ), worst pain (assessed in five trials [7, 8, [19] [20] [21] ), and least pain (assessed in three trials [8, 19, 20] ).
In short, although pain intensity remains the single most common outcome domain assessed in chronic pain clinical trials, there continues to be a lack of standardization in both the specific pain intensity domain assessed (e.g., average, worst, least, or current pain), as well as in the method used to assess that domain (e.g., composite score using ratings from diaries, composite score of multiple domains obtained at a single assessment point, or single ratings of recalled pain intensity). The lack of standardization may be due in part to the lack of empirical evidence supporting the validity of one measure over another [6] . Research is therefore needed to help address this knowledge gap. First, an increased use of similar assessment methods in clinical trials will allow for more direct comparisons in the outcomes between studies. Second, as more is known regarding the specific psychometric strengths and weaknesses of different assessment approaches, researchers will be better able to make informed decisions regarding which measure(s) to use as primary and secondary outcomes in their trials.
Given these issues, the primary aim of this study was to replicate and extend our findings regarding the psychometric properties of different pain intensity outcome measures in the context of a clinical trial, using the same methods we have used in previous studies (e.g., [4, 5] ). As before, we used data from a clinical trial that had a relatively small sample [22] , because issues of sensitivity to treatment effects are particularly important with limited power due to small sample sizes. Specifically, we compared the relative reliability and validity of: 1) four individual ratings (of current pain and 24-hour recall ratings of worst, least, and average pain); and 2) 16 composite scores made up of different combinations of the individual ratings, using data from a previously published study [22] . Based on previous research, we hypothesized that although the reliability of assessment would increase as the number of ratings used to compute composite scores increased, the validity (ability to detect change following treatment) would not substantially increase as the number of ratings used to create the composite scores increase after two ratings. Also based on previous research and on the idea that worst pain ratings provide more "room for improvement" (i.e., a smaller impact of floor effects [4] ), we anticipated that ratings of worst pain would provide larger effects than ratings of average, current, and characteristic pain, which would provide larger effects than ratings of least pain.
Methods

Participants
The participants for the secondary analyses performed here came from a study examining the effects of four interventions (self-hypnosis training, cognitive restructuring, hypnotic cognitive restructuring, and pain education [22] ) on pain intensity in a sample of adults with multiple sclerosis and chronic pain. Eleven of the participants in the original study provided complete data before and after treatment. The average age of these participants was 52.0 years (Range, 42-62). The majority of the participants were women (82%) and white (91%).
Procedures
All of the participants (N 5 11) in this study received four sessions each of all of the treatments (16 treatment sessions in all in different orders; [22] ). Pain intensity data (described in the Measures Section, below) were collected at baseline and after all 16 sessions (i.e., after the participants received all of the interventions), and these data were used in the current analyses.
Measures
We assessed four domains of pain intensity using 0-10 numerical rating scales [23] : 1) current pain; 2) 24-hour recalled worst; 3) least; and 4) average pain. Each of these pain domains was assessed four times just before and just after treatment via telephone interviews conducted on different days within a 7-day window. This procedure yielded 16 individual pain intensity ratings from each assessment period.
As we had done in our previous study [4] , we created pain intensity scores representing five different pain intensity domains (current, average, least, worst, and characteristic pain) that were made up of single ratings and composite scores. The ratings that participants provided during their first interview were used as the single (1-item) ratings of current, average, least, and worst pain. We labeled these scores Current-1, Average-1, Least-1, and Worst-1 (i.e., Pain intensity domainNumber of items). We then computed the means of the intensity ratings provided by the participants during their first and second interviews to create 2-item composites scores of the intensity domains (labeled Current-2, Average-2, Least-2, and Worst-2). We also created the 3-and 4-item composite scores using the same procedures; that is, by computing the mean of the ratings provided by participant during their first three interviews and all four interviews, respectively (labeled Current-3, Average-3, Least-3, Worst-3, Current-4, Average-4, Least-4, Worst-4). Finally, we computed a 1-day score representing characteristic pain [24] by averaging all four of the ratings obtained during the first interview (labeled Characteristic-1; i.e., Pain intensity domains-Number of days of ratings), a 2-day characteristic pain score by averaging the eight ratings obtained during the first two interviews (Characteristic-2), a 3-day characteristic pain score by averaging the 12 ratings obtained during the first three interviews (Characteristic-3), and a 4-day characteristic pain score by average all of the ratings obtained during all four interviews at each assessment point (Characteristic-4). Thus, we computed 20 pain intensity scores (4 single and 16 composite scores) for each assessment period (i.e., baseline and post-treatment).
Data Analysis
We repeated the analyses we performed in our earlier study [4] with the current data so that we could compare the current findings with our previous results. Specifically, we first examined the reliability of the 1-item ratings and 2-item composite scores by computing the Pearson and Spearman correlation coefficients first and second ratings obtained at each assessment period (i.e., at baseline and at post-treatment). We used both parametric and nonparametric procedures given that: 1) parametric approaches are used most often (even in studies with relative few subjects); and 2) nonparametric approaches are generally viewed as more appropriate in studies with low sample sizes. Using both approaches in the current analyses allows us to determine if the statistical approach used has any impact on the findings. Next, we computed internal consistency coefficients (Cronbach's alphas) for all of the composite scores. We evaluated the validity of the different intensity scores by testing their responsivity to the treatments, again using both parametric and nonparametric approaches; that is, by performing t-tests and Wilcoxon signed-rank tests to determine for baseline to post-treatment changes for each measure. Finally, we computed the effect sizes for the baseline to post-treatment changes in each measure (d [25] ) by dividing the mean change by the standard deviation of that change. We performed all analyses using SPSS version 17.0 (IBM, http://www-01.ibm.com/ software/analytics/spss/).
Results
Test-Retest Stability of the Single Ratings and 2-Item Composite Scores
The results of the analyses evaluating the test-retest stability of the single ratings and 2-item composite scores for the measures are presented in Table 1 . As can be seen, the majority of these measures were fairly stable, with many of the single ratings showing good (coefficients 0.80; criterion met by 7 [44%] of the coefficients) and the majority showing at least adequate (coefficients 0.70; criterion met by 10 [63%] of the coefficients) stability. Although fewer of the 2-item composite scores than the single ratings showed good stability (only 4 [25%] of the test-retest stability coefficients for the 2-item composite scores were 0.80), most showed adequate stability ( 0.70; 14 or 88%). In addition, the median stability coefficient did not differ as a function of number of ratings; that is, the median coefficients were 0.75 and 0.74 for the single ratings and 2-item composites, respectively. However, the range of the coefficients between the two types of measures did differ. The coefficients for the single-item ratings ranged from 0.44 to 0.93, and the coefficients for the 2-item composites ranged from 0.66 to 0.94, indicating that the 2-item coefficients were more stable. Among the single ratings, those assessing average pain intensity tended to evidence the highest stability (range of coefficients, 0.81-0.85) and among the 2-item composite scores, the ratings of least pain intensity evidenced the highest levels of stability (range of coefficients, 0.77-0.94).
Internal Consistency of the Composite Scores
The internal consistency coefficients associated with each composite score are presented in Table 2 . Based on guidelines labeling internal consistency coefficients below 0.70 as "unacceptable," 0.70-0.79 as "fair," 0.80-0.89 as "good," and 0.90-0.99 as "excellent" [26] , only one of these coefficients was unacceptable; that for the 2-item worst pain composite assessed at posttreatment (Cronbach's alpha 5 0.66). Moreover, there was some improvement in the internal consistencies of the composite scores as the number of items used to create these composites increased from 2 to 3 (ranges 5 0.66-0.88 and 0.74-0.94, respectively), and virtually no improvement as the number of items increased from 3 to 4 (ranges 5 0.74-0.94 and 0.71-0.91, respectively). Almost all of the internal consistencies of the characteristic pain composite scores (15 or 94%) were in the excellent range, and the one that was not excellent was in the good range.
Validity of the Measures of Pain Intensity
The results of the analyses evaluating the validity of the study measures, as defined by their ability to detect 
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changes in pain with treatment, are presented in Table 3 .
There was a noticeable increase in validity as the number of items used to create the scores increased from 1 to 2, especially for the assessment of current pain, average pain, and worst pain. However, there was virtually no change in the validity of the measures as the number of items used to create the scale scores increased from 2 to 3 (e.g., at the 0.05 alpha level, change in pain became "significant" for average pain but "nonsignificant" for current pain composite scores, and did not change for the either least or worst pain scores) or from 3 to 4. A slight increase in the effect size (and associated significance levels) can be seen as the items used to create the characteristic pain composite scores increased from 4 to 8 (i.e., from the use of assessments from a single day to 2 days). But little improvement can be observed in the validity of characteristic pain measures as the number of assessments increase from 8 to 12 or 16 (i.e., from the use of assessments from 2 to 3 or 2 to 4 days).
More important to the improvement of validity was the consideration of the domain of pain intensity over and above the consideration of the number of items in composite scores. Specifically, the findings indicate that the single ratings and composite scores assessing recalled worst pain were consistently more valid than the single ratings and composite scores assessing any other domain, including current pain, average pain, least pain, and characteristic pain.
Discussion
Three key findings emerged from this study, all of which replicate the results of the analyses performed in a different sample [4] . First, composite scores of pain intensity created from two individual ratings appear to be adequate for validly estimating treatment effects. Second, measures do not appear to need "excellent" (coefficients 0.90) or even "good" (coefficients 0.80) levels of reliability to provide valid estimates of treatment effects. Finally, the findings indicate that substantially more validity can be obtained using recalled "worst" pain ratings instead of any of the other ratings (assessing current, least, average, or characteristic pain intensity) as a primary outcome. These findings have important implications for the selection of measures in pain clinical trials.
Composite Scores Computed from Two Ratings May Be Adequate for Estimating Treatment Effects
The results of an initial examination of the necessity of highly reliable composite scores for detecting treatment effects found that a single rating of 24-hour recalled average pain was about as valid for detecting treatment effects as composite scores made up of anywhere from 2 to 9 ratings [5] . This result surprised us (and others, see [3] ), given that increases in reliably which occur as the number of items used to create composite scores increase (cf., [27] ) should also increase validity [28] . Subsequent analyses did not replicate our initial finding. Instead, and using data from actual clinical trials, we [4] and others [3] found that composites made up of two or more items were needed to provide valid estimates of treatment effects. However, substantial improvements in validity were not observed in these previous studies as the number of ratings used to create the composite scores increased beyond two. Those findings are replicated here. These are extremely important findings to the field given the significant costs associated with a requirement to obtain multiple pain ratings at critical assessment points in clinical trials. These costs not only include the financial costs associated with data collection but also the ethical problem of requiring more assessments from study participants than may be needed, as well as the scientific costs associated with missing data, which increases in likelihood as the number of assessments needed increases [23] .
As we have stated before, however, before we can be confident that this finding would replicate across all or even most populations of individuals with chronic pain involved in a clinical trial, continued replication is needed. In particular, we think that it would be useful to examine the number of ratings that would be needed to detect treatment effects in samples of patients whose pain intensity is known to vary a great deal over time [6] ; for example, individuals with chronic headache or pain problems associated with intermittent breakthrough pain. In such instances, composite scores made up of just two 24-hour recall ratings of pain intensity may prove to be inadequately valid, although it is possible that just one or two 7-day recall ratings may be found to be adequately valid in these populations.
Excessively High Levels of Reliability May Not Be Necessary to Have Valid Estimates of Treatment Effects
Psychometricians note that despite the fact that measures with reliability coefficients 0.90 are labeled as having "excellent" reliability [26] , the efforts needed to increase reliability much more than 0.80 may not yield enough improvements in validity to warrant the costs associated with those efforts [28] . Consistent with this idea, we found a rather weak association between reliability and validity in our previous studies. For example, even though measures of characteristic pain as an average of 4-16 individual ratings of current, worst, least, and average pain evidenced the highest levels of internal consistency (range, 0.89-0.97), their ability to detect treatment effects were never better than the composite measures of worst pain made up of just two individual ratings [4] .
Useful measurement is not only about measuring pain intensity in a highly reliable manner; it is also-and perhaps more importantly-about measuring the correct pain intensity domain, even if the reliability is merely in the "adequate" range. For example, a composite score made up of two 24-hour recalled worst pain ratings evidenced an "inadequate" level of test-retest reliability (correlation coefficient 5 0.52) at post-treatment in our previous studies, much less than the 2-item composites of current (0.81), average (0.74), or least pain (0.85). Yet it was the only measure that detected a significant (P < 0.05) effect [4] . Similarly, in this study, the 2-item composite measure of worst pain had lower levels of test-retest stability than any of the other 2-item composites and the internal consistency of this measure at post-treatment (Cronbach's alpha 5 0.66) was "marginal." Yet this measure was more valid than any of the composite scores assessing any other intensity domain for detecting change in pain with treatment. Moreover, although increasing the number of items used to compute the worst pain composite score increased its reliability as would be expected based on psychometric theory, this increase in reliability was not accompanied by substantial increases in the measure's validity.
Again, we wish to emphasize that we are not saying that reliability is not important. In fact, a measure must have adequate reliability to be valid. The key point we are making is that once a measure has an adequate level of reliability, issues of validity become much more important. In the context of pain clinical trials, a measure with a lower reliability coefficient-if it assesses a domain impacted by the pain treatment being examined-could in fact be more able to detect a treatment effect (i.e., more valid) than a measure with much more reliability that assesses a domain that is less strongly impacted by the treatment. In short, it is better to measure the right outcome domain with adequate reliability than the wrong outcome domain with excellent reliability.
Measures of Recalled Worst Pain May Be More Sensitive to Treatment Effects than Other Measures
While the findings from the available studies, including this study, indicate that one's ability to detect treatment effects does not increase substantially with an increase
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in reliability accomplished by increasing the number of ratings, the findings do indicate that marked changes in validity can occur as a function of the pain intensity domain assessed. The ratings of worst pain were clearly more valid-more able to detect changes in pain with treatment-than any of the other measures. This may be due at least in part to floor effects [4] . For example, there is more room for improvement in worst pain than least pain intensity, at least in individuals with chronic pain. It is also possible that worst pain may be easier to recall accurately than other pain domains, given evidence that events with more emotional valence tend to be recalled more accurately than events associated with less emotion [29] . However, research on memory for pain does not support a conclusion that worst pain intensity is recalled more accurately than other pain intensity domains; recall ratings of all intensity domains, including least, worst, and average, tend to be uniformly accurate (e.g., [30] [31] [32] ). Thus, the impact of recall accuracy is not likely to be playing a significant role in the improved validity of worst pain recall ratings. The findings do, however, suggest that measures of least pain and composite scores that contain information about least pain (e.g., characteristic pain, recalled average pain) may have a restricted range for improvement, which could act to limit the amount of improvement that could be assessed by these scales.
The reader will recall that of 34 studies published in the key Pain journals in 2014, the overwhelming majority assessed average pain, either using a single item rating or a composite score. We were only able to identify four studies that assessed worst pain [7, 8, 19, 21] , and in no case was worst pain the primary outcome domain. The current findings suggest that more investigators should consider both: 1) including measures of worst pain intensity in their trials; and 2) using a measure of worst pain (perhaps computed as a composite score made up of 2 or 3 worst pain ratings) as a primary outcome measure.
Study Limitations
The study has a number of limitations which should be noted and which are shared by a previous study [4] . These include the highly standardized methods used to assess pain intensity (i.e., using trained interviewers), which can potentially result in ratings with more validity, compared with procedures that do not have this level of standardization [6] . It is also not known if the number of pain ratings needed to obtain valid measures would differ if different measures (e.g., faces scales) or different populations (e.g., children) were used. Also, the recall period for the recall measures used here was 24 hours. We suspect that more reliability and perhaps more validity might be possible with the use of measures with longer recall periods, such as 3 days or 1 week [6] . Finally, a strength of the study-a very low sample size-can also be viewed as a weakness. While this allowed us to evaluate the validity of measures in a situation in which sensitivity to change (i.e., study power) is a major concern, it also likely resulted in estimates of reliability that are themselves less reliable than those that would have been obtained had the sample size been larger. All of these limitations support the need for additional research to help determine the overall generalizability of the findings.
Summary and Conclusions
Despite the study's limitations, the findings provide important additional information useful to investigators designing clinical trials for chronic pain treatments. Specifically, they replicate previous findings that outcome can be validly assessed using as few as two pain ratings, and point to measures of recalled worst pain as a potentially viable alternative to measures of average pain in clinical trials, which may boost the overall ability to detect treatment effects. The need to identify effective chronic pain treatments is as urgent as it has ever been [33] ; outcome measures sensitive to the effects of treatment are essential to successfully address this need [1] .
